Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Cappelli

Showing results (151-160 of 196) with videos related to

Pageof 20
Sort By:
European Journal of Heart Failure|May 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersenMarianna Fontana, Amrut V Ambardekar, Francesco Cappelli, et al.
International Journal of Cardiology|September 9, 2023
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosisCarlo Fumagalli, Mattia Zampieri, Alessia Argirò, et al.
Journal of the American College of Cardiology|March 12, 2025
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyDaniel P Judge, Kevin M Alexander, Francesco Cappelli, et al.
European Journal of Heart Failure|May 5, 2022
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosisAldostefano Porcari, Maddalena Rossi, Francesco Cappelli, et al.
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)]Alberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
JACC. Cardiooncology|November 29, 2022
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic ValueAlberto Cipriani, Laura De Michieli, Aldostefano Porcari, et al.
Circulation. Heart Failure|July 2, 2025
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort StudyCarlo Fumagalli, Mattia Zampieri, Roberto Presta, et al.
Circulation. Heart Failure|May 9, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid CardiomyopathyAhmad Masri, Francesco Cappelli, Margot K Davis, et al.
International Journal of Cardiology|March 31, 2025
Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progressionVanda Parisi, Raffaello Ditaranto, Nevio Taglieri, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Pageof 20

Showing results (151-160 of 196) with videos related to

Sort By:
Pageof 20
European Journal of Heart Failure|May 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersenMarianna Fontana, Amrut V Ambardekar, Francesco Cappelli, et al.
International Journal of Cardiology|September 9, 2023
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosisCarlo Fumagalli, Mattia Zampieri, Alessia Argirò, et al.
Journal of the American College of Cardiology|March 12, 2025
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyDaniel P Judge, Kevin M Alexander, Francesco Cappelli, et al.
European Journal of Heart Failure|May 5, 2022
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosisAldostefano Porcari, Maddalena Rossi, Francesco Cappelli, et al.
Giornale Italiano Di Cardiologia (2006)|February 3, 2026
[Light chain amyloidosis: multidisciplinary management and innovative therapeutic strategies. SIC/ANMCO Consensus document of the Italian Cardiac Amyloidosis Network (RIAC)]Alberto Aimo, Giuseppe Vergaro, Vincenzo Castiglione, et al.
JACC. Cardiooncology|November 29, 2022
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic ValueAlberto Cipriani, Laura De Michieli, Aldostefano Porcari, et al.
Circulation. Heart Failure|July 2, 2025
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort StudyCarlo Fumagalli, Mattia Zampieri, Roberto Presta, et al.
Circulation. Heart Failure|May 9, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid CardiomyopathyAhmad Masri, Francesco Cappelli, Margot K Davis, et al.
International Journal of Cardiology|March 31, 2025
Electrocardiogram evolution in Anderson-Fabry disease patients during follow-up in relation to specific treatment and cardiac disease progressionVanda Parisi, Raffaello Ditaranto, Nevio Taglieri, et al.
Journal of the American College of Cardiology|May 21, 2025
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyMathew S Maurer, Daniel P Judge, Julian D Gillmore, et al.
Pageof 20